PS21-2103 Component 3 Combined Evaluation and Work Plan Template

This template is provided as an aid to applicants in preparing the evaluation and work plan for PS21-2103; however, its use is optional.

* Space is provided for brief narrative descriptions of the 5-year plan and Year 1 plan for each strategy, with a suggested limit of 200 words each.
* The title and sections headers in this file are formatted to support accessibility of the document online.
* Applicants may change all text to any 12-point font single spaced to meet requirements stated in the NOFO.
* Text in green can be deleted to reduce the length.

The tables in this template include only the required short-term activities and expected (bolded) outcomes from the PS21-2103 Logic Model.

* Short-term outcomes may be achieved during Years 1–3 of funding; applicants should review and edit these outcomes as needed to indicate what outcomes are expected to be achieved in Year 1.
* Applicants planning to address the intermediate expected (bolded) or remaining (non-bolded) short- or intermediate-term activities/outcomes in Year 1 may copy sections of the template and edit them accordingly.
* The evaluation section can be collapsed appropriately to allow space to explain how evaluation will be conducted and how evaluation results will be used.

## Strategy 3.1 Improve access to services for PWID in settings disproportionately affected by drug use

|  |
| --- |
| **Overall 5-year plan** (200 words): |

|  |
| --- |
| **Detailed Year 1 plan** (200 words): |

### Outcome 3.1.1: Increased access to high-coverage needle-syringe exchange among PWID

### Outcome 3.1.2: Increased linkage to SUD treatment (including MAT among PWID with OUD)

### Outcome 3.1.3: Increased HCV, HIV, and HBV testing among PWID

### Outcome 3.1.4: Increased linkage to treatment services among people with infectious complications (viral hepatitis, HIV, bacterial, fungal) of SUD

### Outcome 3.1.5: Increased receipt of hepatitis B and A vaccination among PWID

| **Year 1 Activities** | **Process Measure(s)** | **Responsible Party/Person** | **Completion Date** |
| --- | --- | --- | --- |
| 1. Form project management team | 1.  2.  3. |  |  |
| 1. Complete rapid health services assessment | 1.  2.  3. |  |  |
| 1. Develop service delivery model | 1.  2.  3. |  |  |
| 1. Prioritize elements of PWID bundle for implementation | 1.  2.  3. |  |  |
| 1. Evaluate access to high-coverage needle-syringe exchange among PWID | 3.1.1.a-b Report containing number, stratified by setting serving PWID (SSPs, SUD treatment programs, hospitals, correctional settings, etc.) of:  a. PWID served  b. Syringes distributed |  |  |
| 1. Evaluate linkage to SUD treatment (including MAT among PWID with OUD) | 3.1.2.a-d Report containing number, stratified by setting serving PWID of:  a. PWID linked to SUD treatment  b. PWID assessed for OUD  c. PWID with OUD  d. PWID with OUD linked to MAT |  |  |
| 1. Evaluate access to HIV, HCV, and HBV testing among PWID | 3.1.3.a-c Report containing number, stratified by setting serving PWID of:  a. Clients tested for anti-HCV  b. Clients screened (anti-HBc, HBsAg, anti-HBs) for HBV  c. Clients screened for HIV |  |  |
| 1. Evaluate linkage to treatment services among people with infectious complications (viral hepatitis, HIV, bacterial, fungal) of SUD | 3.1.4.a-i Report containing number, stratified by setting serving PWID, of:  a. Clients testing positive for anti-HCV  b. Clients positive for anti-HCV tested for HCV RNA  c. Clients testing positive for HCV RNA  d. Clients HCV RNA (+) linked to hepatitis C treatment  e. Clients testing positive for HBsAg  f. Clients HBV (+) linked to hepatitis B care  g. SSP clients testing positive for HIV  h. HIV (+) SSP clients linked to HIV treatment  i. Clients referred for treatment for bacterial or fungal infections |  |  |
| 1. Evaluate receipt of hepatitis B and A vaccination among PWID | 3.1.5.a-d Report containing number, stratified by setting serving PWID, of:  a. Hepatitis A vaccination doses administered to clients  b. Clients who completed hepatitis A vaccination series  c. Hepatitis B vaccination doses administered to clients  d. Clients who completed hepatitis B vaccination series |  |  |